AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 14 analysts
Fundamentals
Fundamentals institutional score is 92 using growth durability 91.5.
Valuation
Valuation institutional score is 65 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 68 using mean target upside 19.6%; dispersion penalty 15.7; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 35 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 10 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and valuation provide support, while technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 37.3% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.17). Confidence: 79%.
Live forward EPS implies next-12-month EPS of ₹69.51. Applying the stock's normalized valuation corridor produces a fair range of ₹2,121.45 to ₹3,083.46, with base value near ₹2,354.30 (+28.3% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹69.51
Forward P/E
26.4x
Base Fair Value
₹2,354.30
Fair Range
₹2,121.45 - ₹3,083.46
Upside To Base
+28.3%
Estimate Source
Live forward EPS
Growth Estimate
+5.4%
5Y Average
29.96
Current
46.51
Overvalued
44.36
Undervalued
30.52
5Y Average
2.71
Current
4.10
Overvalued
3.88
Undervalued
1.66
5Y Average
9.30
Current
8.21
Overvalued
9.72
Undervalued
8.77
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
FORTIS HEALTHCARE LTD FORTISHospitals & Diagnostic Centres | +17.5% | 11.0% | 69.3x Undervalued | -17% vs avg | +1.4% |
PARK MEDI WORLD LIMITED PARKHOSPSHospitals & Diagnostic Centres | +19.3% | 16.1% | 45.8x Undervalued | -45% vs avg | +95.4% |
METROPOLIS HEALTHCARE LTD METROPOLISHospitals & Diagnostic Centres | +16.6% | 11.8% | 58.9x Undervalued | -30% vs avg | +7.6% |
JUPITER LIFE LINE HOSP L JLHLHospitals & Diagnostic Centres | +18.2% | 12.0% | 55.6x Undervalued | -34% vs avg | +12.9% |
GLOBAL HEALTH LIMITED MEDANTAHospitals & Diagnostic Centres | +26.5% | 11.9% | 71.4x Fair | -15% vs avg | +6.9% |
KRISHNA INST OF MED SCI L KIMSHospitals & Diagnostic Centres | +35.3% | 4.8% | 159.9x Premium | +91% vs avg | +10.2% |
ASTER DM QUALITY CARE LTD ASTERDMHospitals & Diagnostic Centres | +21.6% | 6.5% | 142.3x Premium | +70% vs avg | +47.9% |
APOLLO HOSPITALS ENTER. L APOLLOHOSPHospitals & Diagnostic Centres | +18.1% | 7.7% | 66.2x Undervalued | -21% vs avg | +23.2% |
NARAYANA HRUDAYALAYA LTD. trades at a discount (45.4x vs peer avg 83.7x), suggesting potential undervaluation relative to the Hospitals & Diagnostic Centres cohort. Peers include FORTIS HEALTHCARE LTD, PARK MEDI WORLD LIMITED, METROPOLIS HEALTHCARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹1.10K CrJun 2026Latest net profit
₹138 CrJun 2026Latest EPS
₹6.75Jun 2026Net margin
22.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 797 | 852 | 771 | 846 | 872 | 934 | 865 | 919 | 943 | 1,019 | 969 | 1,044 | 1,097 |
| Expenses + | 659 | 688 | 633 | 690 | 715 | 752 | 708 | 743 | 764 | 790 | 764 | 817 | 858 |
| Operating Profit | 138 | 164 | 138 | 156 | 157 | 183 | 157 | 176 | 179 | 229 | 205 | 227 | 239 |
| OPM % | 17% | 19% | 18% | 18% | 18% | 20% | 18% | 19% | 19% | 22% | 21% | 22% | 22% |
| Other Income + | 9 | 14 | 11 | 89 | 14 | 13 | 9 | 107 | 16 | 17 | -29 | 127 | 30 |
| Interest | 13 | 13 | 13 | 14 | 20 | 20 | 21 | 26 | 31 | 29 | 29 | 39 | 34 |
| Depreciation | 38 | 39 | 41 | 44 | 39 | 42 | 43 | 46 | 48 | 46 | 47 | 51 | 48 |
| Profit before tax | 96 | 126 | 95 | 187 | 110 | 134 | 101 | 211 | 117 | 171 | 99 | 264 | 188 |
| Tax % | 18% | 13% | 17% | 15% | 22% | 21% | 22% | 24% | 26% | 20% | 24% | 23% | 27% |
| Net Profit + | 79 | 109 | 79 | 158 | 86 | 106 | 79 | 160 | 87 | 138 | 76 | 202 | 138 |
| EPS in Rs | 3.86 | 5.33 | 3.85 | 7.74 | 4.23 | 5.16 | 3.88 | 7.83 | 4.28 | 6.75 | 3.71 | 9.89 | 6.75 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation